Vyalev is already available in the EU, where it has been approved under the Produodopa brand name since 2022. AbbVie held off on launch until it also got the green light from the European ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.

AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by ...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...

In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development ...